It has shown significant activity and is safe in patients having recurrent DLBCL and in combination with R‐CHOP, which provides potent theoretical evidence for lenalidomide maintenance in responding DLBCL cohort receiving R‐CHOP therapy.25, 26, 27, 28, 29. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.